Darolutamide (Nubeqa) is a novel therapy for metastatic castration-sensitive prostate cancer (mCSPC), a stage where cancer has spread but remains responsive to testosterone-lowering treatments. As a highly selective androgen receptor antagonist, it blocks male hormones that drive tumor growth while minimizing neurological side effects due to its limited penetration of the blood-brain barrier.
The drug works by preventing androgens from binding to receptors, stopping receptor activation and DNA transcription, and reducing cancer cell proliferation. In the ARASENS trial with 1,306 patients, darolutamide combined with androgen deprivation therapy and docetaxel lowered the risk of death by 32%, delayed disease progression, and improved overall survival, establishing it as a key treatment option for mCSPC.
Darolutamide is generally well-tolerated, with mild side effects such as fatigue, rash, and hot flashes. Less common risks include hypertension and fractures. By extending survival while maintaining quality of life, darolutamide represents a meaningful advancement for patients with mCSPC.